- Home
- ENSC vs PALI Comparison
ENSC vs PALI Comparison
Compare ENSC & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- PALI
- Stock Information
- Founded
- ENSC 2003
- PALI 1996
- Country
- ENSC United States
- PALI United States
- Employees
- ENSC N/A
- PALI N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENSC Health Care
- PALI Health Care
- Exchange
- ENSC Nasdaq
- PALI Nasdaq
- Market Cap
- ENSC 2.9M
- PALI 3.2M
- IPO Year
- ENSC N/A
- PALI N/A
- Fundamental
- Price
- ENSC $3.29
- PALI $0.72
- Analyst Decision
- ENSC
- PALI Strong Buy
- Analyst Count
- ENSC 0
- PALI 2
- Target Price
- ENSC N/A
- PALI $23.00
- AVG Volume (30 Days)
- ENSC 4.9M
- PALI 45.4K
- Earning Date
- ENSC 05-12-2025
- PALI 05-12-2025
- Dividend Yield
- ENSC N/A
- PALI N/A
- EPS Growth
- ENSC N/A
- PALI N/A
- EPS
- ENSC N/A
- PALI N/A
- Revenue
- ENSC $5,210,031.00
- PALI N/A
- Revenue This Year
- ENSC N/A
- PALI N/A
- Revenue Next Year
- ENSC N/A
- PALI N/A
- P/E Ratio
- ENSC N/A
- PALI N/A
- Revenue Growth
- ENSC 133.58
- PALI N/A
- 52 Week Low
- ENSC $1.62
- PALI $0.60
- 52 Week High
- ENSC $14.67
- PALI $9.09
- Technical
- Relative Strength Index (RSI)
- ENSC 55.92
- PALI 46.57
- Support Level
- ENSC $3.02
- PALI $0.67
- Resistance Level
- ENSC $4.85
- PALI $0.77
- Average True Range (ATR)
- ENSC 0.40
- PALI 0.05
- MACD
- ENSC 0.27
- PALI 0.02
- Stochastic Oscillator
- ENSC 51.70
- PALI 54.90
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.